Factor 13 deficiency (DF13) is a rare, inherited disorder of blood coagulation that is caused by a lack or absence of coagulation factor XIII in the plasma. This factor plays a key role in the process of fibrin polymerization and stabilization of the formed thrombus, which determines its importance in ensuring hemostasis. With a deficiency of factor XIII, pathological changes in hemostatic processes are observed, which can lead to increased bleeding, hematoma formation and other serious clinical manifestations. The variety of clinical symptoms and their severity can vary, which complicates diagnosis and requires a careful approach to each individual case.
History of the disease and interesting historical facts
The history of factor 13 deficiency research dates back to the mid-20th century, when a link between factor deficiency and susceptibility to hemorrhagic conditions was first demonstrated in the 1960s. The first description of the disease was made in 1970, when Mutations in the F13 gene, responsible for the synthesis of factor XIII, were identified in a group of patients with abnormal hemorrhages. This discovery became a catalyst for more in-depth research in the field of genetics and hemostasis. Subsequently, thanks to modern molecular biology methods, it was possible to identify specific genetic mutations leading to factor XIII deficiency, as well as expand knowledge of the pathogenesis of the disease.
Epidemiology
Epidemiological data on factor 13 deficiency indicate its extreme rarity: according to various sources, the incidence of this disease is approximately 1 in 2-5 million people. Studies have shown that factor XIII deficiency is more common in certain ethnic groups, such as European and Asian populations, with some geographic isolation. Data on the prevalence of factor XIII deficiency in certain populations has contributed to the development of specialized registries and centers for the study and treatment of this disease, which allows for the accumulation of statistical data and improvement of the quality of medical care.
Genetic predisposition to this disease
Factor XIII deficiency is an inherited disorder caused by mutations in the F13A1 gene, which encodes the alpha subunit of factor XIII, and F13B, which encodes the beta subunit. These genes are located on chromosomes 6q26-27 and 1q31, respectively. There are both autosomal recessive and autosomal dominant forms of factor XIII deficiency, with different types of mutations including point changes, deletions, and insertions. These mutations result in impaired inhibition of factor XIII performance and activity, which in turn affects the body's ability to effectively form and stabilize blood clots, increasing the risk of thrombotic events and abnormal hemostasis.
Risk factors for the development of this disease
To date, scientific literature identifies several risk factors that can contribute to the development of factor 13 deficiency:
- Genetic predisposition - the presence of aphiliacs or relatives with similar disorders.
- Certain ethnic groups have mutations in the genes responsible for the synthesis of factor XIII.
- Stressful situations or surgical interventions leading to activation of hemostasis and potential decompensation due to factor deficiency.
- Some toxic substances and drugs that negatively affect protein synthesis in the body.
- Concomitant diseases such as liver cirrhosis or acute infectious processes that may affect the level of blood clotting factors.
Diagnosis of this disease
Diagnosis of factor XIII deficiency is based on a comprehensive approach that includes both clinical and laboratory testing. The main symptoms of the disease can range from disproportionate or severe bleeding to the sudden appearance of hematomas that do not correlate with trauma.
- Laboratory tests: measurement of factor XIII levels using coagulometry and specialized tests.
- Radiological examinations: ultrasound and CT if there is a suspicion of internal bleeding or hematomas.
- Other types of diagnostics: molecular genetic studies to determine the presence of mutations in the F13A1 and F13B genes.
- Differential diagnosis includes exclusion of other conditions that cause hyperreactivity or deficiency of other coagulation factors.
Treatment
Treatment of factor XIII deficiency requires an individual approach, which depends on the severity of the disease and the clinical picture. General treatment usually includes regular infusions of XIII concentrate to correct the deficiency in the body.
- Pharmacological treatment: use of recombinant factor XIII, which standardizes the level of the factor in plasma.
- Surgical treatment may be necessary if serious bleeding occurs directly or if surgical interventions are necessary.
- Other treatments include preventive measures, such as avoiding risk factors that may contribute to bleeding.
List of drugs used to treat this disease
The following drugs are used to treat factor 13 deficiency:
- Factor XIII concentrate (Haemocomplettan) is the mainstay of deficiency correction.
- Recombinant factor XIII (Rixubis) - for the prevention and control of bleeding.
- Cryoprecipitate - can be used in emergency situations for severe bleeding.
Disease monitoring
Monitoring the presumptive status of patients with factor 13 deficiency is important for early detection of possible complications and adequate correction of therapy.
- Monitoring steps include regular check-ups and laboratory tests for factor XIII levels.
- The prognosis with proper therapy is usually positive, but requires constant monitoring.
- Complications may include rebleeding, blood clots, and the need for surgery.
Age-related features of the disease
Factor XIII deficiency may manifest itself at an early age, but the clinical course of the disease in infants and children may differ from that in adults. Children are more likely to have recurrent bleeding with minimal trauma, whereas in adults the risk of developing serious complications such as blood clots may increase with age. Age-related and physiological parameters must be taken into account when prescribing treatment and prevention.
Questions and Answers
- What is factor 13 deficiency? It is a rare inherited disorder caused by a deficiency of clotting factor XIII, resulting in increased bleeding and problems with hemostasis.
- How is factor 13 deficiency diagnosed? Diagnosis is based on laboratory tests for factor XIII levels and molecular genetic studies.
- What is the treatment for factor 13 deficiency? Treatment includes regular infusions of factor XIII, prophylaxis and monitoring of the patient's condition.
- What influences the prognosis of the disease? The prognosis is good with adequate therapy, but may worsen if complications occur.
- Can factor 13 deficiency be inherited? Yes, factor 13 deficiency is inherited in an autosomal recessive or autosomal dominant manner.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov notes that with factor 13 deficiency, it is important to be aware of all the risks associated with the disease. He recommends the following:
- Get regular checkups and tests for factor XIII levels, especially if you have a family history of the condition.
- Review your medical history and tell your doctor about any previous blood clots or bleeding problems.
- Avoid injuries and stressful situations, if possible, change your work schedule to a less stressful mode.
By approaching your therapy consciously and in collaboration with an expert, you can significantly improve your quality of life and minimize the risks associated with factor 13 deficiency.
